Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Tarceva Metabolism with Proton Pump Inhibitors

Please Note: New Treatments Have Emerged Since this Original Post
Author
Howard (Jack) West, MD

I still need to add a post on the more recent history of managing Pancoast tumors, but I wanted to add an important and potentially relevant bit of information I learned today. I'm attending a small meeting in New York and had the opportunity to talk with some folks from the company that makes Tarceva, OSI Pharmaceuticals, who relayed some potentially relevant news people here should know. In follow-up of concerns voiced by several OncTalk members, I had previously asked people at the company what information they have on metabolism of tarceva in people taking a class of drugs called proton pump inhibitors (PPIs), drugs like protonix, nexium, prevacid, and prilosec that block the stomach's ability to make gastric acid. These agents are very helpful in treating gastro-esophageal reflux disease (GERD, or just "heartburn"), and they generally have few side effects. I was told by the folks I spoke to that they were looking into it.

As I described in a prior post back in May, there have been some lingering questions about whether these drugs limit the stomach's ability to absorb oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) like iressa and tarceva. Most of the evidence on this potential interaction is with Iressa, which really isn't commonly used any more in the US, but Iressa and tarceva are similar in so many ways that there would be reason to suspect that the same issue may exist for the commonly used tarceva.

I was just told that they're providing additional information to the FDA based on pharmacokinetic studies (measuring blood levels of drugs over time) that apparently do show that people on PPIs have lower circulating drug levels of tarceva. The person I spoke to didn't have any details available about what the research demonstrated or what the FDA would be doing, but I imagine it may add some language in the official package insert document that advises for doctors to consider this potential interaction when starting someone on tarceva. I don't believe there are data out there to say what would be the "right" dose to use in someone who was continuing on one of these drugs that keeps the stomach from being an acidic environment and thereby limit absorption, but I would be inclined based on this information to advise patients on one of the proton pump inhibitors to stop it if it wasn't definitely necessary while they were on tarceva. In some other situations when people need an acidic environment to absorb a medication, you can take it with something acidic at the same time, like orange juice, coca cola, or vitamin C (ascorbic acid), but I'd probably prefer to avoid the issue by having someone suspend taking both a PPI and tarceva at the same time.

I'll let you know more when I have more to tell.

Next Previous link

Previous PostNext Post

Related Content

Image
Trial data ASCO 2024
Video
In this video series from ASCO 2024, Drs. Aakash Desai and Fauwzi Abu Rous discuss trial dates and clinical data as presented at the 2024 ASCO. To watch the complete playlist, click here.         
Image
Bladder Cancer Video Library 2024
Video
Dr. Petros Grivas discusses intravesical treatment for patients with nonmuscle invasive, or early-stage, bladder cancer, the importance of participating in clinical trials for bladder cancer, combination therapy options for patients with metastatic or incurable bladder cancer, and the importance of family history of cancer and discussing that history with your doctor.
Image
Case Based Panel
Video
The panel discusses treatment options for a patient diagnosed with EGFR Exon 19 Deletion NSCLC and examines data from the Laura Trial, a patient with a smoking history and diagnosis of small cell lung cancer, and how the Adriatic Study factors into decisions, and a patient with NSCLC adenocarcinoma, and a EGFR Exon 21 L858R Alteration, and how data from the Flaura 2 Trial can impact treatment decisions.

Forum Discussions

Hi elysianfields and welcome to Grace.  I'm sorry to hear about your father's progression. 

 

Unfortunately, lepto remains a difficult area to treat.  Recently FDA approved the combo Lazertinib and Amivantamab...

Hello Janine, thank you for your reply.

Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...

Hi elysianfields,

 

That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...

Recent Comments

JOIN THE CONVERSATION
I could not find any info on…
By JanineT GRACE … on
Hi elysianfields,

 

That's…
By JanineT GRACE … on
Hello Janine, thank you for…
By elysianfields on
EGFR
By happybluesun on